Doctorglasses Chain Faces Valuation Challenges Amid Declining Profits and Rising Costs

Doctorglasses Chain Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a notable shift in its valuation metrics, which have been categorized as very expensive. The company's P/E ratio stands at 63, while its Price to Book Value is recorded at 7.86. Additionally, the EV to EBIT and EV to EBITDA ratios are at 50.02 and 26.11, respectively, indicating a premium valuation compared to industry standards. In terms of performance indicators, the company has reported a return on capital employed (ROCE) of 22.27% and a return on equity (ROE) of 12.56%. However, the recent financial quarter ending September 2025 showed flat results, with a decline in profits by 3.1% year-over-year. The interest coverage ratio is notably high at 2,454.98, yet the raw material costs have increased by 7.75% year-over-year, adding pressure to the financial outlook. Overall, the stock's technical indicators have transitioned from bearish to mildly bearish, reflecting a complex market position. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.